| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Allos Therapeutics, Inc. |
| 7000 North Broadway, Suite 400, Denver, CO 80221 * (303) 426-6262 |
| Business Description | The company is a pharmaceutical company focused on developing and commercializing innovative small molecule drugs, initially for improving cancer treatments. |
| Offering Information Company has | |||
| Trading As | ALTH (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 1/26/00 |
| Domestic Shares Offered | 5,000,000 | Offer Date | 3/27/00 |
| Foreign Shares Offered | 0 | Filing Range | $17.00 - $19.00 |
| Company Shares | 5,000,000 | Offer Price | $18.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.260 |
| Gross Proceeds | $90,000,000 | Selling | $0.750 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 22,800,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| SG Cowen | Lead Manager | (212) 495-6000 |
| Prudential Vector Healthcare | Co-manager | (800) 546-1231 |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | ||
| Revenues | - | - | - | - | - | - | - |
| Income from Oper. | -2.462 | -4.373 | -6.691 | -9.195 | -10.783 | - | - |
| Net Income | -2.384 | -4.053 | -6.513 | -8.574 | -10.473 | - | - |
| E.P.S | -1.190 | -1.530 | -2.180 | -2.710 | -6.240 | - | - |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -9.50 | - | - | ||||
| Cash Flow - Inv. | 1.02 | - | - | ||||
| Cash Flow - Fin. | 9.42 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 10.21 | Current Assets | 9.93 | Current Ratio | 8.67 |
| Total Liab. | 1.21 | Current Liab. | 1.15 | Debt Ratio | 11.90% |
| Total Equity | 8.99 | Working Cap. | 8.78 | Debt to Equity Ratio | 0.14 |
| Cash | 2.60 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development activities, including clinical trials, process development and manufacturing support, and for general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Perkins Coie |
| Bank's Law Firm | Brown & Wood |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Entities affiliated with Oak Investment Partners | 13.50 | |
| Entities affiliated with Sprout Capital | 13.40 | |
| Johnson & Johnson Development Corporation | 12.40 | |
| Entities affiliated with Marquette Venture Partners | 10.20 | |
| International BM Biomedicine Holdings, Inc. | 9.70 | |
| Entities affiliated with Schroder Ventures International Life Sciences Fund | 8.90 | |
| Entities affiliated with INVESCO Private Capital, Inc. | 7.70 | |
| Note: represents ownership of 5% or more prior to the offering. | ||